Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 5/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.35 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.35 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.35 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.35 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641478 | 1.00 | CCR6 (0.44) | CCR6HCRTR1HCRTR2MGLLPRKAB2 | |
| SCHEMBL639965 | 0.93 | CCR6 (0.41) | CCR6HCRTR1HCRTR2MGLLPRKAB2 | |
| SCHEMBL639964 | 0.93 | CCR6 (0.41) | CCR6HCRTR1HCRTR2MGLLPRKAB2 | |
| SCHEMBL640960 | 0.87 | CCR6 (0.39) | CCR6HCRTR1HCRTR2MGLLALDH1A1 | |
| SCHEMBL10008094 | 0.87 | CCR6 (0.39) | CCR6HCRTR1HCRTR2MGLLPRKAB2 | |
| SCHEMBL640145 | 0.87 | CCR6 (0.39) | CCR6HCRTR1HCRTR2MGLLALDH1A1 | |
| SCHEMBL640289 | 0.87 | CCR6 (0.39) | CCR6HCRTR1HCRTR2MGLLPRKAB2 | |
| SCHEMBL639624 | 0.87 | CCR6 (0.38) | CCR6HCRTR1HCRTR2MGLLPRKAB2 | |
| SCHEMBL639625 | 0.87 | CCR6 (0.38) | CCR6HCRTR1HCRTR2MGLLPRKAB2 | |
| SCHEMBL641450 | 0.87 | CCR6 (0.38) | CCR6HCRTR1HCRTR2MGLLPRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791148-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-8119676-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | Abbott GmbH & Co. HG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | CCR6 4653/4885HCRTR1 951/4885HCRTR2 641/4885 |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | CCR6 4653/4885HCRTR1 951/4885HCRTR2 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.